{ "company": "Natera", "ticker": "NTRA", "period": { "from": "2026-03-06", "to": "2026-04-05", "days": 30 }, "sentiment_breakdown": { "positive": 44, "negative": 34, "neutral": 28 }, "synthesis": { "executive_summary": "Sentiment analysis for Natera (NTRA) from 2026-03-06 to 2026-04-05. Analyzed 106 items across FDA and news sources.", "key_findings": [], "overall_sentiment": "neutral" }, "top_positive": [ { "title": "Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.", "date": "2026 Mar 2", "source": "pubmed", "score": 0.753 }, { "title": "Dakota Wealth Management Buys Shares of 5,921 Natera, Inc. $NTRA", "date": "2026-03-29", "source": "alpha_vantage", "score": 0.66 }, { "title": "CIBC Private Wealth Group LLC Buys 53,086 Shares of Natera, Inc. $NTRA", "date": "2026-03-20", "source": "alpha_vantage", "score": 0.66 }, { "title": "Cell-Free DNA (cfDNA) Testing Market Size to Reach USD 39.43 Billion by 2035; Growth is Propelling Owing to Continuous Growth of Genomics Research Globally | SNS Insider", "date": "2026-03-10", "source": "news", "score": 0.66 }, { "title": "Oncology Precision Medicine Market Trends and Investment Opportunities 2026-2030 - Advancements in CAR-T and Gene Therapies Propel Precision Oncology Growth", "date": "2026-03-27", "source": "news", "score": 0.637 }, { "title": "Natera, Inc. $NTRA Shares Sold by Assenagon Asset Management S.A.", "date": "2026-03-28", "source": "alpha_vantage", "score": 0.572 }, { "title": "Wealth Enhancement Advisory Services LLC Has $11.48 Million Stock Position in Natera, Inc. $NTRA", "date": "2026-03-27", "source": "alpha_vantage", "score": 0.494 }, { "title": "Translating ctDNA into cutaneous melanoma care: An international expert survey.", "date": "2026 Mar 1", "source": "pubmed", "score": 0.494 }, { "title": "Natera co-founder Jonathan Sheena sells shares worth $908,301", "date": "2026-03-21", "source": "alpha_vantage", "score": 0.477 }, { "title": "Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI).", "date": "2026 Mar 6", "source": "pubmed", "score": 0.477 } ], "top_negative": [ { "title": "Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.", "date": "2026 Apr 1", "source": "pubmed", "score": -1.0 }, { "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research", "date": "2026-03-27", "source": "news", "score": -0.945 }, { "title": "Testing for hereditary cancer genes in men: a missed opportunity for cancer prevention.", "date": "2026-04-05", "source": "pubmed", "score": -0.848 }, { "title": "The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.832 }, { "title": "Utility of Circulating Tumor DNA-Based Liquid Biopsies in Patients with Cancer Receiving Immunotherapy.", "date": "2026-04-05", "source": "pubmed", "score": -0.791 }, { "title": "Blood test helped some women over 70 with breast cancer avoid surgery", "date": "2026-03-31", "source": "alpha_vantage", "score": -0.765 }, { "title": "Signatera Data in Older Breast Cancer Patients Could Be A Game Changer For Natera (NTRA)", "date": "2026-04-01", "source": "alpha_vantage", "score": -0.66 }, { "title": "Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip Surgery", "date": "2026-03-31", "source": "alpha_vantage", "score": -0.66 }, { "title": "Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.", "date": "2026-04-05", "source": "pubmed", "score": -0.66 }, { "title": "A Mobile Exhibition to Advance Cancer Prevention Awareness: A Cross-Sectional Evaluation Using the RE-AIM Framework.", "date": "2026 Apr 1", "source": "pubmed", "score": -0.66 } ], "raw_data": { "total_items": 106, "items": [ { "source": "alpha_vantage", "title": "Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,000 Shares of Stock", "url": "https://www.marketbeat.com/instant-alerts/natera-nasdaqntra-insider-solomon-moshkevich-sells-3000-shares-of-stock-2026-04-03/", "date": "2026-04-04", "summary": "Natera insider Solomon Moshkevich recently sold 3,000 shares of the company's stock for over $600,000, reducing his stake by 1.99%. This transaction is part of a pattern of ongoing insider disposals by Moshkevich, who has made several other significant sales since January. Despite these insider sales, Natera recently exceeded quarterly EPS and revenue estimates and holds a \"Moderate Buy\" consensus analyst rating with a target price of $253.47.", "sentiment_score": -0.189864, "sentiment_label": "Somewhat-Bearish", "relevance_score": 0.992362, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera president sells $606,899 in NTRA stock", "url": "https://m.investing.com/news/insider-trading-news/natera-president-sells-606899-in-ntra-stock-93CH-4597490?ampMode=1", "date": "2026-04-04", "summary": "Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NTRA), sold 3,000 shares of company stock for approximately $606,899 on April 1, 2026. These sales were executed under a pre-arranged trading plan, and Moshkevich still directly owns 147,882 shares. The article also touches on recent company developments, including new genetic tests and board expansion, and an adjusted price target by Morgan Stanley.", "sentiment_score": 0.146014, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera SEC. sold $1.7m in NTRA stock", "url": "https://www.investing.com/news/insider-trading-news/natera-sec-sold-17m-in-ntra-stock-93CH-4597491", "date": "2026-04-04", "summary": "Daniel Rabinowitz, SEC. and Chief Legal Officer of Natera, Inc. (NASDAQ:NTRA), sold 8,400 shares of common stock totaling $1.7 million on April 1, 2026. This insider sale followed a 55% surge in Natera's stock over the past year, placing it among InvestingPro's most overvalued companies. The company has recently launched new genomics tests and seen a price target adjustment from Morgan Stanley.", "sentiment_score": 0.084042, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera (NTRA) president sells 3,000 shares under Rule 10b5-1 plan", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-7cfdbe66df68.html", "date": "2026-04-04", "summary": "Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NTRA), sold 3,000 shares of common stock on April 1, 2026, through an open-market transaction. These sales were pre-arranged under a Rule 10b5-1 trading plan adopted on November 26, 2024. Following these transactions, Moshkevich directly holds 147,882 shares of Natera.", "sentiment_score": -0.253804, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera (NASDAQ: NTRA) legal chief sells 8,400 shares in preset 10b5-1 plan", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-0e25ff27fe5c.html", "date": "2026-04-04", "summary": "Natera's Secretary and Chief Legal Officer, Daniel Rabinowitz, sold 8,400 shares of the company's common stock on April 1, 2026. The sales were conducted through a pre-arranged Rule 10b5-1 trading plan at weighted average prices between $200.47 and $205.50 per share. Following these transactions, Rabinowitz still holds 224,885 shares of Natera common stock.", "sentiment_score": 0.02345, "sentiment_label": "Neutral", "relevance_score": 0.320669, "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "alpha_vantage", "title": "Natera SEC. sold $1.7m in NTRA stock", "url": "https://m.investing.com/news/insider-trading-news/natera-sec-sold-17m-in-ntra-stock-93CH-4597491?ampMode=1", "date": "2026-04-04", "summary": "Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER of Natera, Inc. (NASDAQ:NTRA), sold 8,400 shares of common stock for $1.7 million on April 1, 2026, through a Rule 10b5-1 trading plan. This sale occurred as Natera's stock surged 55% over the past year. In other news, Natera launched Zenith genomics and its Signatera test showed promising results in cancer studies.", "sentiment_score": -0.244704, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera (NTRA) chair exercises 41,708 options, now holds 2.35M shares", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-2cb7102ee209.html", "date": "2026-04-02", "summary": "Matthew Rabinowitz, Executive Chairman of Natera (NTRA), exercised 41,708 stock options at a strike price of $9.59 per share. This transaction increased his direct holdings to 2,352,480 shares of Natera Common Stock, with an additional 58,292 stock options and 5,000 indirect shares through his spouse. The filing confirms no shares were sold and the options were fully exercisable.", "sentiment_score": 0.006096, "sentiment_label": "Neutral", "relevance_score": 0.347353, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera Expands Board, Appoints Eric Rubin as Director", "url": "https://www.tipranks.com/news/company-announcements/natera-expands-board-appoints-eric-rubin-as-director", "date": "2026-04-01", "summary": "Natera has expanded its Board of Directors from ten to eleven members, appointing Eric Rubin as an independent Class I director effective March 26, 2026. Dr. Rubin will also join the Nominating, Corporate Governance and Compliance Committee and will receive standard director compensation. This move emphasizes Natera's commitment to independent oversight and regulatory compliance, with Dr. Rubin having no related-party ties to the company.", "sentiment_score": 0.291002, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "Eric Rubin appointed to Natera board as Class I director", "url": "https://www.tradingview.com/news/tradingview:cf61fa6d2a1b1:0-eric-rubin-appointed-to-natera-board-as-class-i-director/", "date": "2026-04-01", "summary": "Natera has appointed Eric Rubin to its Board of Directors as a Class I director, effective March 26, 2026. This appointment increased the board's size from ten to eleven members, with Rubin also joining the Nominating, Corporate Governance and Compliance Committee. He will receive standard cash and equity compensation for non-employee directors, with his initial equity award vesting over three years.", "sentiment_score": 0.365077, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Eric Rubin joins Natera (NASDAQ: NTRA) board as independent director", "url": "https://www.stocktitan.net/sec-filings/NTRA/8-k-natera-inc-reports-material-event-10e242e4f351.html", "date": "2026-04-01", "summary": "Natera, Inc. has expanded its Board of Directors to eleven members by appointing Eric Rubin as a Class I independent director, effective March 26, 2026. Dr. Rubin will serve on the Nominating, Corporate Governance and Compliance Committee and will receive standard cash and equity compensation, with his initial equity award vesting in three equal installments. An Indemnification Agreement has also been put in place for his service to the company.", "sentiment_score": 0.234372, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "J. Safra Sarasin Holding AG Makes New Investment in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-j-safra-sarasin-holding-ag-makes-new-investment-in-natera-inc-ntra-2026-04-01/", "date": "2026-04-01", "summary": "J. Safra Sarasin Holding AG recently acquired a new stake of 12,331 shares in Natera, Inc. (NASDAQ:NTRA), valued at approximately $2.83 million, during the fourth quarter. This move aligns with other institutional investors, contributing to Natera's 99.90% institutional ownership. Despite beating Q4 earnings estimates with $0.35 EPS and $665.5 million in revenue, the company remains unprofitable with significant insider selling recorded, while analysts hold a \"Moderate Buy\" consensus.", "sentiment_score": 0.226008, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Signatera Data in Older Breast Cancer Patients Could Be A Game Changer For Natera (NTRA)", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/signatera-data-in-older-breast-cancer-patients-could-be-a-ga", "date": "2026-04-01", "summary": "Natera's Signatera molecular residual disease test has shown promising results in a new study, allowing older women with early-stage ER+/HER2- breast cancer to opt for primary endocrine therapy over surgery. This development could reshape Natera's investment narrative by reinforcing Signatera's clinical utility and potentially influencing future reimbursement decisions for various oncology indications. Despite optimistic forecasts, analysts remain cautious about the company's path to profitabili", "sentiment_score": 0.439862, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Natera, Inc. $NTRA Shares Sold by Allspring Global Investments Holdings LLC", "url": "https://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-shares-sold-by-allspring-global-investments-holdings-llc-2026-04-01/", "date": "2026-04-01", "summary": "Allspring Global Investments Holdings LLC significantly reduced its stake in Natera, Inc. (NTRA) by 4.4% in the fourth quarter, selling 20,896 shares and retaining 454,498 shares. This comes amidst heavy insider selling, including transactions by CEO Steven Chapman and another insider, totaling over $74.1 million in the last quarter, though insiders still hold 5.63% of the stock. Despite this, institutional investors collectively own 99.90% of Natera's stock, and the company reported an EPS beat", "sentiment_score": 0.05084, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip Surgery", "url": "https://www.benzinga.com/news/health-care/26/03/51576065/nateras-signatera-data-suggests-select-breast-cancer-patients-could-skip-surgery", "date": "2026-03-31", "summary": "Natera's Signatera molecular residual disease (MRD) test has shown promising results, indicating that select breast cancer patients could potentially avoid surgery. A study published in Clinical Cancer Research demonstrated Signatera's ability to identify older women with early-stage ER+/HER2- breast cancer who can be effectively managed with primary endocrine therapy. The study highlights Signatera's strong predictive accuracy and early-detection capabilities, supporting its utility for non-sur", "sentiment_score": 0.028685, "sentiment_label": "Neutral", "relevance_score": 0.318696, "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Avoiding Lag: Real-Time Signals in (NTRA) Movement", "url": "https://news.stocktradersdaily.com/news_release/12/Avoiding_Lag:_Real-Time_Signals_in_NTRA_Movement_033126033202_1774985522.html", "date": "2026-03-31", "summary": "This article provides a detailed analysis of Natera Inc. (NASDAQ: NTRA) movement, highlighting weak near-term sentiment despite long-term strength. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes a strong risk-reward setup, real-time signals, and multi-timeframe insights for traders.", "sentiment_score": 0.218648, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.586, "confidence": 0.59 } }, { "source": "alpha_vantage", "title": "Natera, Inc. $NTRA Shares Sold by Zevenbergen Capital Investments LLC", "url": "https://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-shares-sold-by-zevenbergen-capital-investments-llc-2026-03-31/", "date": "2026-03-31", "summary": "Zevenbergen Capital Investments LLC has reduced its stake in Natera, Inc. by 18% in the fourth quarter, selling 70,994 shares, although the stock still constitutes 1.6% of its portfolio. Despite this, other institutional investors have shown increased interest, while significant insider selling, including by the CFO and CEO, has occurred. Analysts maintain a \"Moderate Buy\" consensus for Natera, with an average price target of $253.47, following strong quarterly results that beat expectations.", "sentiment_score": 0.001852, "sentiment_label": "Neutral", "relevance_score": 0.330104, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Blood test helped some women over 70 with breast cancer avoid surgery", "url": "https://www.stocktitan.net/news/NTRA/signatera-tm-mrd-identifies-breast-cancer-patients-who-can-forgo-ro16r8unwe94.html", "date": "2026-03-31", "summary": "A new study published in Clinical Cancer Research indicates that Natera's Signatera™ molecular residual disease (MRD) test can identify older women with early-stage ER+/HER2- breast cancer who can safely forgo surgery and be managed with primary endocrine therapy. The study found that 100% of patients who were MRD-negative at baseline remained progression-free. These findings suggest that Signatera can help inform treatment decisions, potentially reducing the need for surgery in a vulnerable pat", "sentiment_score": 0.48493, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.765, "confidence": 0.77 } }, { "source": "alpha_vantage", "title": "Natera Inc (NTRA) Shares Down 6.88% on Mar 30", "url": "https://www.gurufocus.com/news/8756834/natera-inc-ntra-shares-down-688-on-mar-30?mobile=true", "date": "2026-03-30", "summary": "Natera Inc (NTRA) shares dropped 6.88% on March 30, closing at $182.65. Wall Street analysts project an average price target of $253.56, indicating a 38.82% upside, with an \"Outperform\" consensus recommendation. GuruFocus estimates a fair value of $213.11, suggesting a 16.68% upside from the current price.", "sentiment_score": -0.396973, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Dakota Wealth Management Buys Shares of 5,921 Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-dakota-wealth-management-buys-shares-of-5921-natera-inc-ntra-2026-03-29/", "date": "2026-03-29", "summary": "Dakota Wealth Management purchased 5,921 shares of Natera, Inc. (NASDAQ:NTRA), valued at approximately $1.36 million, in the fourth quarter, joining other institutional investors increasing their stake. Despite strong institutional ownership (99.90%), company insiders, including CEO Steven Leonard Chapman, have recently sold a significant number of shares. Natera exceeded Q4 earnings expectations with $0.35 EPS against an estimated -$0.46, and analysts maintain a \"Moderate Buy\" rating with an av", "sentiment_score": 0.26379, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "DAVENPORT & Co LLC Takes Position in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-davenport-co-llc-takes-position-in-natera-inc-ntra-2026-03-28/", "date": "2026-03-28", "summary": "DAVENPORT & Co LLC has initiated a new position in Natera, Inc. (NASDAQ: NTRA) during Q4, acquiring 14,032 shares valued at approximately $3.215 million. While institutional investors hold a significant portion of the stock, recent insider activity shows sales by CEO Steven Leonard Chapman and other insiders totaling over $74 million in the last 90 days. Natera recently beat quarterly earnings and revenue estimates and holds a \"Moderate Buy\" consensus rating from analysts with an average price t", "sentiment_score": 0.327181, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera, Inc. $NTRA Shares Sold by Assenagon Asset Management S.A.", "url": "https://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-shares-sold-by-assenagon-asset-management-sa-2026-03-28/", "date": "2026-03-28", "summary": "Assenagon Asset Management S.A. significantly reduced its stake in Natera, Inc. (NASDAQ:NTRA) by 85.5% in the fourth quarter, selling over 261,000 shares. Despite Natera reporting a surprise earnings beat with $0.35 EPS against a -$0.46 consensus, and revenue exceeding estimates, the company still has negative margins and analysts anticipate a negative EPS for the current year. Insider selling has also been observed, with major officers offloading shares, while institutional investors maintain a", "sentiment_score": -0.140128, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.572, "confidence": 0.57 } }, { "source": "alpha_vantage", "title": "A Look At Natera (NTRA) Valuation After Recent Share Price Weakness", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/a-look-at-natera-ntra-valuation-after-recent-share-price-wea", "date": "2026-03-28", "summary": "Natera (NTRA) has experienced recent share price weakness, though its long-term shareholder returns remain strong. Despite the pullback, the company is considered undervalued by some intrinsic estimates and analyst price targets, with a fair value pegged at $260.65 per share due to growth in molecular diagnostics. However, its current P/S ratio is above the industry average, suggesting less room for error if growth falters.", "sentiment_score": 0.32421, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "alpha_vantage", "title": "Natera Inc (NTRA) Shares Down 4.14% on Mar 27", "url": "https://www.gurufocus.com/news/8750024/natera-inc-ntra-shares-down-414-on-mar-27", "date": "2026-03-28", "summary": "Shares of Natera Inc (NTRA) dropped 4.14% on March 27, reaching an intraday low of $187.86 before settling at $188.02. This stock price is 26.66% below its 52-week high and 49.96% above its 52-week low. Wall Street analysts have an average target price of $253.56 for NTRA, indicating an \"Outperform\" status and a potential upside of 34.86%.", "sentiment_score": -0.219089, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know", "url": "https://www.tradingview.com/news/stockstory:97d4478af094b:0-elanco-tandem-diabetes-fortrea-natera-and-myriad-genetics-shares-plummet-what-you-need-to-know/", "date": "2026-03-27", "summary": "Several stocks including Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics experienced significant drops in the afternoon trading session. This market downturn is attributed to rising uncertainty from the U.S.-Iran conflict and policy deadlines set by the Trump administration, leading to a dip in consumer confidence. Despite the broader market reaction, the article highlights potential buying opportunities in these quality stocks given that markets often overreact to news.", "sentiment_score": -0.248833, "sentiment_label": "Somewhat-Bearish", "relevance_score": 0.93262, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Vanguard disaggregates holdings; reports 0 shares for Natera (NTRA)", "url": "https://www.stocktitan.net/sec-filings/NTRA/schedule-13g-a-natera-inc-amended-passive-investment-disclosure-b9cf16bd8fd9.html", "date": "2026-03-27", "summary": "Vanguard has reported 0 beneficial shares owned in Natera (NTRA) following an internal realignment effective January 12, 2026. This change means that certain Vanguard subsidiaries will now report their holdings separately, although their investment strategies remain unchanged. The filing indicates that The Vanguard Group itself no longer holds beneficial ownership over securities held by these disaggregated subsidiaries.", "sentiment_score": 0.03473, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Wealth Enhancement Advisory Services LLC Has $11.48 Million Stock Position in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-wealth-enhancement-advisory-services-llc-has-1148-million-stock-position-in-natera-inc-ntra-2026-03-27/", "date": "2026-03-27", "summary": "Wealth Enhancement Advisory Services LLC increased its stake in Natera, Inc. (NASDAQ:NTRA) by 25.9% to holdings worth $11.48 million, contributing to institutional investors owning 99.90% of the company. Natera surpassed Q4 earnings and revenue estimates but remains unprofitable with negative margins. Despite significant insider selling totaling $74.09 million in the last 90 days, analysts maintain a \"Moderate Buy\" rating with an average price target of $253.47.", "sentiment_score": 0.127063, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "alpha_vantage", "title": "Is It Time To Reassess Natera (NTRA) After Its Recent Share Price Pullback", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/is-it-time-to-reassess-natera-ntra-after-its-recent-share-pr", "date": "2026-03-26", "summary": "This article examines Natera (NTRA) after a recent share price pullback, noting its strong 1-year and 3-year returns despite a current decline. Using two valuation methods, a Discounted Cash Flow (DCF) analysis suggests Natera is 37.8% undervalued, while a Price-to-Sales (P/S) ratio comparison indicates it might be overvalued relative to its Fair Ratio. The article encourages investors to use \"Narratives\" on the Simply Wall St platform to form their own valuation based on differing assumptions.", "sentiment_score": 0.281182, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "If You Invested $1000 In Natera Stock 10 Years Ago, You Would Have This Much Today", "url": "https://www.sahmcapital.com/news/content/if-you-invested-1000-in-natera-stock-10-years-ago-you-would-have-this-much-today-2026-03-25", "date": "2026-03-25", "summary": "Natera (NTRA) has significantly outperformed the market over the last decade, with an average annual return of 36.62%. An initial investment of $1000 in Natera stock 10 years ago would now be worth $22,576.05. This highlights the powerful effect of compounded returns on investment growth over time.", "sentiment_score": 0.53928, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera (NTRA) Launches Zenith Genomic Assay", "url": "https://www.insidermonkey.com/blog/natera-ntra-launches-zenith-genomic-assay-1723130/", "date": "2026-03-24", "summary": "Natera, Inc. (NASDAQ: NTRA) has commercially launched Zenith, a whole-genome sequencing assay designed to improve the diagnosis of rare genetic conditions and shorten the diagnostic journey for millions of Americans. This new clinical tool aims to address the significant unmet needs and economic burden associated with rare diseases. The launch follows a recent price target reduction for Natera by Morgan Stanley, though the firm maintained an Overweight rating.", "sentiment_score": 0.243611, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera, Inc. (NASDAQ:NTRA) Given Consensus Recommendation of \"Moderate Buy\" by Brokerages", "url": "https://www.marketbeat.com/instant-alerts/natera-inc-nasdaqntra-given-consensus-recommendation-of-moderate-buy-by-brokerages-2026-03-24/", "date": "2026-03-24", "summary": "Eighteen brokerages have given Natera, Inc. (NASDAQ:NTRA) a \"Moderate Buy\" consensus recommendation, with an average 12-month price target of $253.47. Despite beating Q4 earnings and revenue estimates, the company remains unprofitable with negative net margin and return on equity. Recent insider selling by the CFO and CEO has been noted, although institutional investors have increased their holdings.", "sentiment_score": 0.121591, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera Inc (NTRA) Stock Price Up 2.86% on Mar 23", "url": "https://www.gurufocus.com/news/8736353/natera-inc-ntra-stock-price-up-286-on-mar-23", "date": "2026-03-23", "summary": "Shares of Natera Inc (NTRA) rose by 2.86% in mid-day trading on March 23, closing at $200.87. Wall Street analysts forecast an average target price of $253.56, indicating an upside of 26.23%, with an \"Outperform\" recommendation. GuruFocus estimates a one-year GF Value of $213.32 for NTRA, suggesting a 6.2% upside.", "sentiment_score": 0.345761, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Natera co-founder Jonathan Sheena sells shares worth $908,301", "url": "https://www.investing.com/news/insider-trading-news/natera-cofounder-jonathan-sheena-sells-shares-worth-908301-93CH-4574014", "date": "2026-03-21", "summary": "Natera co-founder Jonathan Sheena sold 5,360 shares of the company's common stock for a total of $908,301 across two transactions in March 2026. Despite a year-to-date decline, Natera's stock gained 4% in the week of the sales and analysts maintain a bullish outlook with price targets up to $300. The company's market capitalization stands at $27.81 billion, though InvestingPro analysis suggests the stock is currently overvalued.", "sentiment_score": 0.018633, "sentiment_label": "Neutral", "relevance_score": 0.304216, "sentiment": { "label": "positive", "score": 0.477, "confidence": 0.48 } }, { "source": "alpha_vantage", "title": "Natera (NASDAQ: NTRA) co-founder reports 4,570-share planned stock sale", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-fc5307cf2697.html", "date": "2026-03-21", "summary": "Natera's co-founder, Jonathan Sheena, reported planned sales of 4,570 shares of common stock on March 18 and March 20, 2026. The sales were executed at prices ranging from approximately $196 to $201 per share under pre-arranged Rule 10b5-1 trading plans adopted in June and December 2024. These transactions included both direct holdings and shares held by Caraluna 1 Trust and Caraluna 2 Trust, with Sheena disclaiming beneficial ownership of the trust-held shares.", "sentiment_score": -0.206908, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Jonathan Sheena reports multiple share sales for NTRA (NASDAQ: NTRA)", "url": "https://www.stocktitan.net/sec-filings/NTRA/144-natera-inc-sec-filing-9fbc92a076b5.html", "date": "2026-03-20", "summary": "Jonathan Sheena, an affiliate of Natera, Inc. (NASDAQ: NTRA), has reported multiple proposed sales of Common shares through a Form 144 filing. The filing details various transactions by Sheena, including sales of 2,981 shares for $699,755.00 on January 20, 2026, 3,070 shares for $614,710.00 on March 2, 2026, and 3,070 shares for $608,370.00 on March 18, 2026, handled by Charles Schwab & Co., Inc. These transactions are considered routine dispositions by an affiliate.", "sentiment_score": 0.016918, "sentiment_label": "Neutral", "relevance_score": 0.331925, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera Inc (NTRA) Shares Gap Down to $196.73 on Mar 20", "url": "https://www.gurufocus.com/news/8731347/natera-inc-ntra-shares-gap-down-to-19673-on-mar-20", "date": "2026-03-20", "summary": "Shares of Natera Inc (NTRA) dropped by 2.96% to $196.73 on March 20, trading at 23.26% below its 52-week high and 56.91% above its 52-week low. Analysts forecast an average target price of $253.56, indicating a potential upside of 28.89%, with a consensus rating of \"Outperform.\" GuruFocus estimates the fair value (GF Value) at $213.41, suggesting an 8.48% upside.", "sentiment_score": -0.209047, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "CIBC Private Wealth Group LLC Buys 53,086 Shares of Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-cibc-private-wealth-group-llc-buys-53086-shares-of-natera-inc-ntra-2026-03-20/", "date": "2026-03-20", "summary": "CIBC Private Wealth Group LLC increased its stake in Natera, Inc. by 44.2% in the third quarter, acquiring 53,086 shares to hold a total of 173,088 shares valued at approximately $27.86 million. Natera reported better-than-expected quarterly earnings and revenue, though it remains unprofitable. The stock currently has a \"Moderate Buy\" consensus rating from analysts with an average target price of $253.47.", "sentiment_score": 0.004238, "sentiment_label": "Neutral", "relevance_score": 0.309407, "sentiment": { "label": "positive", "score": 0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Groupama Asset Managment Has $12.42 Million Stock Holdings in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-groupama-asset-managment-has-1242-million-stock-holdings-in-natera-inc-ntra-2026-03-19/", "date": "2026-03-19", "summary": "Groupama Asset Management significantly reduced its stake in Natera, Inc. by 25.9%, selling 26,989 shares and now holding 77,184 shares valued at $12.42 million. This move occurred alongside substantial insider sales from Natera's CFO and CEO, totaling over $28 million. Despite these sales and unprofitability, Natera exceeded earnings and revenue estimates last quarter, and analysts currently maintain a \"Moderate Buy\" consensus for the stock.", "sentiment_score": 0.112931, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.361, "confidence": 0.36 } }, { "source": "alpha_vantage", "title": "Natera, Inc. (NTRA) reports preliminary Q4 revenue", "url": "https://www.msn.com/en-us/health/other/natera-inc-ntra-reports-preliminary-q4-revenue/ar-AA1VfrkV?ocid=BingNewsVerp&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-03-18", "summary": "This article reports that Natera, Inc. (NTRA) has released its preliminary revenue figures for the fourth quarter. The specific financial details would be included in the full article.", "sentiment_score": 0.116896, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Jonathan Sheena files Rule 144 notice selling shares (NASDAQ: NTRA)", "url": "https://www.stocktitan.net/sec-filings/NTRA/144-natera-inc-sec-filing-84ed2b9376b2.html", "date": "2026-03-18", "summary": "Jonathan Sheena has filed a Rule 144 notice indicating proposed sales of common stock in Natera, Inc. (NASDAQ: NTRA). The filing details several disposition dates and share amounts, such as 3,163 shares on January 21, 2026, and 3,070 shares on March 2, 2026, with transactions handled by Charles Schwab & Co., Inc. An analyst noted this as a routine procedural disclosure for resale.", "sentiment_score": 0.015936, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Faithward Advisors LLC Invests $3.52 Million in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-faithward-advisors-llc-invests-352-million-in-natera-inc-ntra-2026-03-18/", "date": "2026-03-18", "summary": "Faithward Advisors LLC acquired a new stake of 21,843 shares in Natera, Inc. (NASDAQ:NTRA) during the third quarter, valued at approximately $3.52 million. This investment comes amidst significant insider selling, with 318,344 shares worth about $74.09 million sold in the last three months, though Natera recently beat earnings estimates. The company holds a \"Moderate Buy\" consensus rating from analysts with an average target price of $253.47.", "sentiment_score": 0.325785, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Livforsakringsbolaget Skandia Omsesidigt Buys 17,100 Shares of Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-livforsakringsbolaget-skandia-omsesidigt-buys-17100-shares-of-natera-inc-ntra-2026-03-18/", "date": "2026-03-18", "summary": "Livforsakringsbolaget Skandia Omsesidigt significantly increased its stake in Natera, Inc. (NASDAQ:NTRA) by 213.9% in the third quarter, acquiring 17,100 additional shares to hold a total of 25,095 shares valued at $4.04 million. This move comes as Natera reported a strong quarterly beat, with EPS of $0.35 against an estimated -$0.46 and revenues of $665.5 million versus $600.7 million. Despite recent insider selling totaling $74.09 million, analysts maintain a \"Moderate Buy\" rating with an aver", "sentiment_score": 0.302227, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera (NTRA) director sells 122 shares under 10b5-1 trading plan", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-951529ddbdf6.html", "date": "2026-03-18", "summary": "A Natera, Inc. director, Rowan E. Chapman, sold 122 shares of common stock at $191.38 per share on March 13, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. This transaction, representing a small portion of his holdings, leaves Chapman with 5,752 direct shares. The filing of this Form 4 indicates a neutral impact with a negative sentiment.", "sentiment_score": -0.142219, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Insider Selling: Natera (NASDAQ:NTRA) Director Sells 122 Shares of Stock", "url": "https://www.marketbeat.com/instant-alerts/insider-selling-natera-nasdaqntra-director-sells-122-shares-of-stock-2026-03-17/", "date": "2026-03-18", "summary": "Natera (NASDAQ:NTRA) Director Rowan Chapman sold 122 shares of the company's stock on March 13th, valued at $23,348.36, decreasing his stake by 2.08%. Despite recent sales, Natera exceeded earnings expectations with EPS of $0.35 and revenue of $665.5M, holding a consensus \"Moderate Buy\" rating among analysts with a price target of $253.47. The company specializes in genetic testing technologies for reproductive health, oncology, and organ transplantation.", "sentiment_score": 0.139, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera director Chapman sells $23348 in shares", "url": "https://www.investing.com/news/insider-trading-news/natera-director-chapman-sells-23348-in-shares-93CH-4567331", "date": "2026-03-18", "summary": "Rowan E. Chapman, a director at Natera, Inc. (NASDAQ:NTRA), sold 122 shares of the company's common stock for $23,348 on March 13, 2026. This transaction was part of a Rule 10b5-1 trading plan and leaves Chapman with 5752 shares. The company has recently seen positive news regarding its Signatera assay and launched a new whole-genome sequencing test, while analysts have maintained favorable ratings.", "sentiment_score": 0.202402, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Natera (NTRA) chair Rabinowitz exercises options and sells 200,000 shares", "url": "https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-75a54712ba4c.html", "date": "2026-03-17", "summary": "Natera's executive chairman, Matthew Rabinowitz, exercised stock options for 200,000 shares at $9.59 per share and subsequently sold all 200,000 shares in open-market transactions. The sales occurred at weighted average prices between approximately $186 and $198 per share, under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following these transactions, Rabinowitz directly holds 2,310,772 shares of Natera common stock, with an additional 5,000 shares held indirectly by his sp", "sentiment_score": 0.027989, "sentiment_label": "Neutral", "relevance_score": 0.307586, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Holocene Advisors LP Decreases Stock Holdings in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-holocene-advisors-lp-decreases-stock-holdings-in-natera-inc-ntra-2026-03-17/", "date": "2026-03-17", "summary": "Holocene Advisors LP significantly reduced its stake in Natera, Inc. (NASDAQ:NTRA) by 43.8% in the third quarter, selling over 250,000 shares. Despite this, other institutional investors like JPMorgan Chase & Co., Norges Bank, and Vanguard Group Inc. increased their positions, indicating mixed institutional sentiment. The article also highlights recent insider stock sales by Natera's CFO and CEO, totaling over $28 million.", "sentiment_score": 0.02374, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Assessing Natera (NTRA) Valuation After New Signatera Data And Zenith Genomics Launch", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/assessing-natera-ntra-valuation-after-new-signatera-data-and", "date": "2026-03-17", "summary": "Natera's stock is under recent scrutiny following the release of new peer-reviewed studies on its Signatera cancer assay and the commercial launch of Zenith genomics. Despite a recent share price jump, the stock has shown fading near-term momentum compared to its stronger one and three-year returns. While some models suggest Natera is undervalued significantly, its price-to-sales ratio indicates higher market expectations.", "sentiment_score": 0.32947, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Boothbay Fund Management LLC Increases Position in Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-boothbay-fund-management-llc-increases-position-in-natera-inc-ntra-2026-03-17/", "date": "2026-03-17", "summary": "Boothbay Fund Management LLC significantly increased its stake in Natera, Inc. by 847.3% in the third quarter, now holding 17,497 shares valued at $2.82 million. Despite institutional ownership being high at 99.90%, insiders sold a notable amount of shares. Natera recently exceeded earnings expectations, reporting $0.35 EPS against a -$0.46 consensus, with a \"Moderate Buy\" analyst rating and a target of $253.47.", "sentiment_score": 0.445843, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Farallon Capital Management LLC Sells 568,357 Shares of Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-farallon-capital-management-llc-sells-568357-shares-of-natera-inc-ntra-2026-03-16/", "date": "2026-03-16", "summary": "Farallon Capital Management LLC significantly reduced its stake in Natera, Inc. by 11.8% in the third quarter, selling 568,357 shares. Despite this reduction, Natera remains Farallon's fifth-largest holding, comprising 2.8% of its portfolio. Other institutional investors have also adjusted their positions, while analysts provide a range of ratings from \"Strong Buy\" to \"Sell\" with an average target price of $253.47.", "sentiment_score": -0.257655, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Fred Alger Management LLC Buys 41,303 Shares of Natera, Inc. $NTRA", "url": "https://www.marketbeat.com/instant-alerts/filing-fred-alger-management-llc-buys-41303-shares-of-natera-inc-ntra-2026-03-16/", "date": "2026-03-16", "summary": "Fred Alger Management LLC increased its stake in Natera, Inc. by 1.7% in Q3, purchasing 41,303 shares to hold a total of 2,451,779 shares valued at approximately $394.66 million. Natera reported strong quarterly earnings, beating revenue and EPS estimates, but remains unprofitable for the year with analysts forecasting a negative EPS of -1.49 for the current year. Despite insider selling, institutional ownership is high, and analysts have a \"Moderate Buy\" consensus with an average price target o", "sentiment_score": 0.242869, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2026-04-01", "url": "https://www.sec.gov/Archives/edgar/data/1604821/000110465926038519/0001104659-26-038519-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research", "description": "With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action", "url": "https://www.globenewswire.com/news-release/2026/03/27/3263970/0/en/Colorectal-Cancer-Advocates-Urge-Congress-to-Fund-New-Research.html", "date": "2026-03-27", "published_at": "2026-03-27T16:31:00Z", "sentiment": { "label": "negative", "score": -0.945, "confidence": 0.95 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Oncology Precision Medicine Market Trends and Investment Opportunities 2026-2030 - Advancements in CAR-T and Gene Therapies Propel Precision Oncology Growth", "description": "Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The \"Oncology Precision Medicine Market Report 2026\" has been added to ResearchAndMarkets.com's offering. ...", "url": "https://www.globenewswire.com/news-release/2026/03/27/3263857/28124/en/Oncology-Precision-Medicine-Market-Trends-and-Investment-Opportunities-2026-2030-Advancements-in-CAR-T-and-Gene-Therapies-Propel-Precision-Oncology-Growth.html", "date": "2026-03-27", "published_at": "2026-03-27T14:44:00Z", "sentiment": { "label": "positive", "score": 0.637, "confidence": 0.64 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results", "description": "NASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quarter results:", "url": "https://www.globenewswire.com/news-release/2026/03/26/3263407/0/en/IMDX-Submits-GraftAssureDx-for-FDA-Review-and-Reports-Q4-2025-Results.html", "date": "2026-03-26", "published_at": "2026-03-26T20:05:00Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Predictive Biomarkers Market to Reach USD 156.85 Billion by 2035; Rising Adoption of Precision Medicine and Targeted Therapies Driving Market Growth – SNS Insider", "description": "Rising Chronic Disease Burden, AI-Driven Biomarker Discovery, and Expanding Companion Diagnostics Pipelines Fuel Unprecedented Market Expansion. Rising Chronic Disease Burden, AI-Driven Biomarker Discovery, and Expanding Companion Diagnostics Pipelines Fuel U…", "url": "https://www.globenewswire.com/news-release/2026/03/17/3257053/0/en/Predictive-Biomarkers-Market-to-Reach-USD-156-85-Billion-by-2035-Rising-Adoption-of-Precision-Medicine-and-Targeted-Therapies-Driving-Market-Growth-SNS-Insider.html", "date": "2026-03-17", "published_at": "2026-03-17T11:45:00Z", "sentiment": { "label": "negative", "score": -0.477, "confidence": 0.48 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Cell-Free DNA (cfDNA) Testing Market Size to Reach USD 39.43 Billion by 2035; Growth is Propelling Owing to Continuous Growth of Genomics Research Globally | SNS Insider", "description": "Cell-Free DNA Testing Market to reach USD 39.43 Bn by 2035, driven by rising adoption of non-invasive prenatal screening, liquid biopsy....", "url": "https://www.globenewswire.com/news-release/2026/03/10/3252493/0/en/Cell-Free-DNA-cfDNA-Testing-Market-Size-to-Reach-USD-39-43-Billion-by-2035-Growth-is-Propelling-Owing-to-Continuous-Growth-of-Genomics-Research-Globally-SNS-Insider.html", "date": "2026-03-10", "published_at": "2026-03-10T09:00:00Z", "sentiment": { "label": "positive", "score": 0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41933595", "title": "Safety profile of KRAS G12C inhibitors combined with thoracic radiation therapy.", "authors": "Miller DG et al.", "journal": "Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41933595/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "pubmed", "pmid": "41932032", "title": "Translating ctDNA into cutaneous melanoma care: An international expert survey.", "authors": "Geidel G et al.", "journal": "European journal of cancer (Oxford, England : 1990)", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41932032/", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "pubmed", "pmid": "41926089", "title": "Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects.", "authors": "Park CS et al.", "journal": "JAMA oncology", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41926089/", "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41924551", "title": "Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.", "authors": "Eslinger C et al.", "journal": "Drug design, development and therapy", "date": "2026-04-05", "url": "https://pubmed.ncbi.nlm.nih.gov/41924551/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41922555", "title": "A Mobile Exhibition to Advance Cancer Prevention Awareness: A Cross-Sectional Evaluation Using the RE-AIM Framework.", "authors": "Fey T et al.", "journal": "Journal of cancer education : the official journal of the American Association for Cancer Education", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41922555/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41919756", "title": "How genetic counselors in North America describe their professional identity.", "authors": "Schwartz L et al.", "journal": "Journal of genetic counseling", "date": "2026-04-05", "url": "https://pubmed.ncbi.nlm.nih.gov/41919756/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41919242", "title": "Testing for hereditary cancer genes in men: a missed opportunity for cancer prevention.", "authors": "Szmyd C et al.", "journal": "Frontiers in oncology", "date": "2026-04-05", "url": "https://pubmed.ncbi.nlm.nih.gov/41919242/", "sentiment": { "label": "negative", "score": -0.848, "confidence": 0.85 } }, { "source": "pubmed", "pmid": "41917040", "title": "Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.", "authors": "Liang J et al.", "journal": "Nature communications", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41917040/", "sentiment": { "label": "negative", "score": -1.0, "confidence": 1.0 } }, { "source": "pubmed", "pmid": "41912809", "title": "Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.", "authors": "Wainberg ZA et al.", "journal": "Nature medicine", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41912809/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41910021", "title": "A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.", "authors": "Johnson ML et al.", "journal": "Future oncology (London, England)", "date": "2026-04-05", "url": "https://pubmed.ncbi.nlm.nih.gov/41910021/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41908612", "title": "Three People With Recurrent Nephrolithiasis and Heterozygous ABCC6 Mutations.", "authors": "Farrell D et al.", "journal": "Kidney medicine", "date": "2026-04-05", "url": "https://pubmed.ncbi.nlm.nih.gov/41908612/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41904847", "title": "Evaluating the safety and efficacy of chemotherapy in patients with relapsed small cell lung cancer combined with allopurinol and MycoPhenolate (CLAMP).", "authors": "Knapp B et al.", "journal": "Lung cancer (Amsterdam, Netherlands)", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41904847/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41903996", "title": "Utility of Circulating Tumor DNA-Based Liquid Biopsies in Patients with Cancer Receiving Immunotherapy.", "authors": "Teixeira MF et al.", "journal": "Surgical oncology clinics of North America", "date": "2026-04-05", "url": "https://pubmed.ncbi.nlm.nih.gov/41903996/", "sentiment": { "label": "negative", "score": -0.791, "confidence": 0.79 } }, { "source": "pubmed", "pmid": "41903855", "title": "Organ-specific differences in the epidemiology of cytomegalovirus infections in high-risk (CMV D+R-) solid organ transplant recipients with prolonged follow-up: a ten-year experience.", "authors": "Heldman MR et al.", "journal": "American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41903855/", "sentiment": { "label": "positive", "score": 0.153, "confidence": 0.15 } }, { "source": "pubmed", "pmid": "41903539", "title": "Advancing precision health discovery in a genetically diverse health system.", "authors": "Haas R et al.", "journal": "Cell", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41903539/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41896510", "title": "ASO Author Reflections: New Insights for Personalized HIPEC Strategies in Colorectal Cancer Peritoneal Metastases.", "authors": "Gupta P et al.", "journal": "Annals of surgical oncology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41896510/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41895280", "title": "Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.", "authors": "Bandlamudi C et al.", "journal": "Cancer cell", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41895280/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41891361", "title": "Disparities in Genetic Testing: Evaluation of Reproductive Carrier Screening in the United States.", "authors": "Parmar S et al.", "journal": "Genetics in medicine : official journal of the American College of Medical Genetics", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41891361/", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41883872", "title": "Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer.", "authors": "Qadri F et al.", "journal": "Therapeutic advances in medical oncology", "date": "2026-04-05", "url": "https://pubmed.ncbi.nlm.nih.gov/41883872/", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41882705", "title": "Expression of complement pathway genes is associated with progression of idiopathic pulmonary fibrosis.", "authors": "Swaminathan AC et al.", "journal": "Respiratory research", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41882705/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41880691", "title": "CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer (AFT-46).", "authors": "Martin LW et al.", "journal": "Lung cancer (Amsterdam, Netherlands)", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41880691/", "sentiment": { "label": "negative", "score": -0.542, "confidence": 0.54 } }, { "source": "pubmed", "pmid": "41875915", "title": "Proton therapy for oropharyngeal cancer: survival, toxicity, and functional outcomes.", "authors": "Vargas CE", "journal": "Lancet (London, England)", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41875915/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41874669", "title": "Risk factors for immune checkpoint inhibitor colitis: a retrospective multi-center cohort study using electronic health records.", "authors": "Chu DHT et al.", "journal": "Cancer immunology, immunotherapy : CII", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874669/", "sentiment": { "label": "negative", "score": -0.052, "confidence": 0.05 } }, { "source": "pubmed", "pmid": "41874648", "title": "Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).", "authors": "Mollica V et al.", "journal": "Cancer immunology, immunotherapy : CII", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874648/", "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "pubmed", "pmid": "41873434", "title": "Advanced artificial intelligence vs simpler models for 1-year death prediction among patients receiving hemodialysis.", "authors": "K K et al.", "journal": "JAMIA open", "date": "2026-04-05", "url": "https://pubmed.ncbi.nlm.nih.gov/41873434/", "sentiment": { "label": "positive", "score": 0.052, "confidence": 0.05 } }, { "source": "pubmed", "pmid": "41872254", "title": "Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients.", "authors": "Nixon AB et al.", "journal": "Scientific reports", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41872254/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41864057", "title": "Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer.", "authors": "Corti C et al.", "journal": "Breast (Edinburgh, Scotland)", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41864057/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41862950", "title": "Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.", "authors": "Holida M et al.", "journal": "Orphanet journal of rare diseases", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41862950/", "sentiment": { "label": "positive", "score": 0.753, "confidence": 0.75 } }, { "source": "pubmed", "pmid": "41862439", "title": "Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.", "authors": "Varga C et al.", "journal": "Blood cancer journal", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41862439/", "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "pubmed", "pmid": "41861751", "title": "Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia.", "authors": "Rugo HS et al.", "journal": "ESMO open", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41861751/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41860673", "title": "Photochemical transformation of paracetamol sensitized by humic acid: pH-dependent pathways and mechanisms.", "authors": "Barrera A et al.", "journal": "Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41860673/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41858873", "title": "Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies.", "authors": "Sanchez-Cespedes M et al.", "journal": "JTO clinical and research reports", "date": "2026-04-05", "url": "https://pubmed.ncbi.nlm.nih.gov/41858873/", "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41854411", "title": "Use of ctDNA in Older Women with ER+ Breast Cancer to Facilitate Surgical De-escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies.", "authors": "Carleton N et al.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41854411/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41851467", "title": "Thymic health and immunotherapy outcomes in patients with cancer.", "authors": "Bernatz S et al.", "journal": "Nature", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41851467/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41851087", "title": "The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study.", "authors": "Lee V et al.", "journal": "Nature communications", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41851087/", "sentiment": { "label": "negative", "score": -0.832, "confidence": 0.83 } }, { "source": "pubmed", "pmid": "41850040", "title": "Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301.", "authors": "Abou-Alfa GK et al.", "journal": "ESMO open", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41850040/", "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "pubmed", "pmid": "41843049", "title": "Clinically Meaningful, Patient-Centered Endpoints for Real-World Evidence Generation in Breast Cancer: Perspectives from the Multidisciplinary TRIUMPH Initiative.", "authors": "Khozin S et al.", "journal": "Advances in therapy", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41843049/", "sentiment": { "label": "positive", "score": 0.186, "confidence": 0.19 } }, { "source": "pubmed", "pmid": "41840743", "title": "Microsimulation model to identify suboptimal recurrence detection in patients with colorectal cancer following the current standard of care.", "authors": "Samur S et al.", "journal": "BMJ open", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41840743/", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41838361", "title": "Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal Dissection.", "authors": "Herb J et al.", "journal": "Annals of surgical oncology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41838361/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41837795", "title": "AI-assisted Qualitative Research on Kidney Failure Treatment Decisions.", "authors": "Bicki A et al.", "journal": "Transplantation", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41837795/", "sentiment": { "label": "negative", "score": -0.511, "confidence": 0.51 } }, { "source": "pubmed", "pmid": "41833593", "title": "Comparing DSA-negative and DSA-positive antibody-mediated rejection in heart transplants: results from the Trifecta-Heart study.", "authors": "Madill-Thomsen KS et al.", "journal": "The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41833593/", "sentiment": { "label": "positive", "score": 0.178, "confidence": 0.18 } }, { "source": "pubmed", "pmid": "41830435", "title": "Impact of everolimus-related interstitial lung disease on subsequent treatment in patients with metastatic breast cancer.", "authors": "Kiyohara H et al.", "journal": "The oncologist", "date": "2026 Mar 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41830435/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41830429", "title": "Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity.", "authors": "Torrado C et al.", "journal": "The oncologist", "date": "2026 Mar 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41830429/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41826432", "title": "Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.", "authors": "Tarantino P et al.", "journal": "NPJ precision oncology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41826432/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41817930", "title": "ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.", "authors": "Kuemmel S et al.", "journal": "Annals of surgical oncology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41817930/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41807638", "title": "Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics.", "authors": "Choo J et al.", "journal": "Nature reviews. Clinical oncology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41807638/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41793510", "title": "A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis.", "authors": "Giordano A et al.", "journal": "Breast cancer research and treatment", "date": "2026 Mar 7", "url": "https://pubmed.ncbi.nlm.nih.gov/41793510/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41791849", "title": "Novel insights into autoimmune gastritis: clinical profile and gastric neoplastic risk from an international multicentre study.", "authors": "Lenti MV et al.", "journal": "Gut", "date": "2026 Mar 6", "url": "https://pubmed.ncbi.nlm.nih.gov/41791849/", "sentiment": { "label": "positive", "score": 0.052, "confidence": 0.05 } }, { "source": "pubmed", "pmid": "41790338", "title": "Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI).", "authors": "Shibuki T et al.", "journal": "International journal of clinical oncology", "date": "2026 Mar 6", "url": "https://pubmed.ncbi.nlm.nih.gov/41790338/", "sentiment": { "label": "positive", "score": 0.477, "confidence": 0.48 } }, { "source": "pubmed", "pmid": "41741368", "title": "Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study.", "authors": "Manji GA et al.", "journal": "The oncologist", "date": "2026 Mar 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41741368/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } } ] } }